Cargando…

Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary

We report on children with cancer in Hungary suffering from COVID-19, surveying a 13-months-long period of time. We performed a retrospective clinical trial studying the medical documentation of children treated in seven centers of the Hungarian Pediatric Oncology-Hematology Group. About 10% of chil...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Judit, Szűcs-Farkas, Dóra, Szegedi, István, Csóka, Monika, Garami, Miklós, Tiszlavicz, Lilla Györgyi, Hauser, Péter, Kriván, Gergely, Csanádi, Krisztina, Ottóffy, Gábor, Nagy, Béla, Kiss, Csongor, Kovács, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008132/
https://www.ncbi.nlm.nih.gov/pubmed/35431663
http://dx.doi.org/10.3389/pore.2022.1610261
_version_ 1784686980662034432
author Müller, Judit
Szűcs-Farkas, Dóra
Szegedi, István
Csóka, Monika
Garami, Miklós
Tiszlavicz, Lilla Györgyi
Hauser, Péter
Kriván, Gergely
Csanádi, Krisztina
Ottóffy, Gábor
Nagy, Béla
Kiss, Csongor
Kovács, Gábor
author_facet Müller, Judit
Szűcs-Farkas, Dóra
Szegedi, István
Csóka, Monika
Garami, Miklós
Tiszlavicz, Lilla Györgyi
Hauser, Péter
Kriván, Gergely
Csanádi, Krisztina
Ottóffy, Gábor
Nagy, Béla
Kiss, Csongor
Kovács, Gábor
author_sort Müller, Judit
collection PubMed
description We report on children with cancer in Hungary suffering from COVID-19, surveying a 13-months-long period of time. We performed a retrospective clinical trial studying the medical documentation of children treated in seven centers of the Hungarian Pediatric Oncology-Hematology Group. About 10% of children admitted to tertiary hemato-oncological centers for anti-neoplastic treatment or diagnosis for de novo malignancies were positive for SARS-CoV-2 infection. Nearly two-thirds of the infected patients were asymptomatic or had only mild symptoms but showed seropositivity by 1–4.5 months after positive PCR. One third of the SARS-CoV-2-positive children were hospitalized due to symptomatic COVID-19. Five children required antiviral treatment with remdesivir. One child was referred to the intensive care unit, requiring intubation and mechanical ventilation. Delay in the scheduled anti-cancer treatment did not exceed 2 weeks in the majority (89%) of cases. There was only one patient requiring treatment deferral longer than a month. There was no COVID-19-related death in patients under 18 years of age, and nor was multisystem inflammatory syndrome diagnosed. In conclusion, SARS-CoV-2 infection did not represent an untoward risk factor among children with cancer in Hungary.
format Online
Article
Text
id pubmed-9008132
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90081322022-04-15 Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary Müller, Judit Szűcs-Farkas, Dóra Szegedi, István Csóka, Monika Garami, Miklós Tiszlavicz, Lilla Györgyi Hauser, Péter Kriván, Gergely Csanádi, Krisztina Ottóffy, Gábor Nagy, Béla Kiss, Csongor Kovács, Gábor Pathol Oncol Res Pathology and Oncology Archive We report on children with cancer in Hungary suffering from COVID-19, surveying a 13-months-long period of time. We performed a retrospective clinical trial studying the medical documentation of children treated in seven centers of the Hungarian Pediatric Oncology-Hematology Group. About 10% of children admitted to tertiary hemato-oncological centers for anti-neoplastic treatment or diagnosis for de novo malignancies were positive for SARS-CoV-2 infection. Nearly two-thirds of the infected patients were asymptomatic or had only mild symptoms but showed seropositivity by 1–4.5 months after positive PCR. One third of the SARS-CoV-2-positive children were hospitalized due to symptomatic COVID-19. Five children required antiviral treatment with remdesivir. One child was referred to the intensive care unit, requiring intubation and mechanical ventilation. Delay in the scheduled anti-cancer treatment did not exceed 2 weeks in the majority (89%) of cases. There was only one patient requiring treatment deferral longer than a month. There was no COVID-19-related death in patients under 18 years of age, and nor was multisystem inflammatory syndrome diagnosed. In conclusion, SARS-CoV-2 infection did not represent an untoward risk factor among children with cancer in Hungary. Frontiers Media S.A. 2022-03-31 /pmc/articles/PMC9008132/ /pubmed/35431663 http://dx.doi.org/10.3389/pore.2022.1610261 Text en Copyright © 2022 Müller, Szűcs-Farkas, Szegedi, Csóka, Garami, Tiszlavicz, Hauser, Kriván, Csanádi, Ottóffy, Nagy, Kiss and Kovács. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pathology and Oncology Archive
Müller, Judit
Szűcs-Farkas, Dóra
Szegedi, István
Csóka, Monika
Garami, Miklós
Tiszlavicz, Lilla Györgyi
Hauser, Péter
Kriván, Gergely
Csanádi, Krisztina
Ottóffy, Gábor
Nagy, Béla
Kiss, Csongor
Kovács, Gábor
Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary
title Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary
title_full Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary
title_fullStr Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary
title_full_unstemmed Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary
title_short Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary
title_sort clinical course of covid-19 disease in children treated with neoplastic diseases in hungary
topic Pathology and Oncology Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008132/
https://www.ncbi.nlm.nih.gov/pubmed/35431663
http://dx.doi.org/10.3389/pore.2022.1610261
work_keys_str_mv AT mullerjudit clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT szucsfarkasdora clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT szegediistvan clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT csokamonika clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT garamimiklos clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT tiszlaviczlillagyorgyi clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT hauserpeter clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT krivangergely clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT csanadikrisztina clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT ottoffygabor clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT nagybela clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT kisscsongor clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary
AT kovacsgabor clinicalcourseofcovid19diseaseinchildrentreatedwithneoplasticdiseasesinhungary